GlassScriptPhysician profile
Sneha Patel
NPI 1841765880
$3,209.30
in general payments reported to CMS, 2019-2025
26 companies · $1,508 in 2025
The $1,508 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $210 · 2023: $581 · 2024: $695 · 2025: $1,508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,683 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.48 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $545.75 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $422.69 | 2023-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $359.82 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $291.92 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $257.78 | 2023-2025 | Cuvitru, Takhzyro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $180.59 | 2023-2025 | |
| Optinose US, INC. | $164.46 | 2023-2025 | |
| Genzyme Corporation | $143.18 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $100.59 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Grt US Holding, INC. | $95.97 | 2021-2022 | |
| Abbvie INC. | $59.59 | 2023 | |
| Grifols USA, LLC | $38.98 | 2024-2025 | Xembify |
| Kaleo, INC. | $28.57 | 2022-2023 | Auvi-Q |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.65 | 2024 | Invega Sustenna |
| Arbor Pharmaceuticals, INC. | $25.51 | 2021 | |
| Alk-Abello, INC | $23.66 | 2023 | Odactra, Grastek, Ragwitek |
| Lilly USA, LLC | $22.64 | 2025 | Ebglyss |
| Medtronic, INC. | $18.55 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.13 | 2025 | Alvesco |
| Leo Pharma INC. | $17.01 | 2023 | Adbry |
| Redhill Biopharma INC. | $14.40 | 2021 | |
| Pharming Healthcare, INC. | $13.53 | 2025 | Ruconest |
| Forte Bio-Pharma LLC | $13.36 | 2021 | |
| Baudax Bio INC. | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.